Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198159 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
A Phase 2 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00198159 is a Phase 2 study that was terminated before completion, run by Indiana University. The registered enrollment target is 21 participants.
The verdict
NCT00198159, a Phase 2 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.
Interventions
- DRUG ZD1839 Iressa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2002-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198159
The ClinicalTrials.gov registry entry for NCT00198159 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD1839 Iressa is the first listed.
NCT00198159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198159 about?
NCT00198159 is a clinical study titled "A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR". This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.
What is the current status of trial NCT00198159?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2002-09. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00198159?
The interventions under investigation include: ZD1839 Iressa (DRUG).
Who is sponsoring clinical trial NCT00198159?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.